Phosphotyrosine profiling of human cerebrospinal fluid

Gajanan Sathe, Chan Hyun Na, Santosh Renuse, Anil Madugundu, Marilyn Albert, Abhay Moghekar, Akhilesh Pandey

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Cerebrospinal fluid (CSF) is an important source of potential biomarkers that affect the brain. Biomarkers for neurodegenerative disorders are needed to assist in diagnosis, monitoring disease progression and evaluating efficacy of therapies. Recent studies have demonstrated the involvement of tyrosine kinases in neuronal cell death. Thus, neurodegeneration in the brain is related to altered tyrosine phosphorylation of proteins in the brain and identification of abnormally phosphorylated tyrosine peptides in CSF has the potential to ascertain candidate biomarkers for neurodegenerative disorders. Methods: In this study, we used an antibody-based tyrosine phosphopeptide enrichment method coupled with high resolution Orbitrap Fusion Tribrid Lumos Fourier transform mass spectrometer to catalog tyrosine phosphorylated peptides from cerebrospinal fluid. The subset of identified tyrosine phosphorylated peptides was also validated using parallel reaction monitoring (PRM)-based targeted approach. Results: To date, there are no published studies on global profiling of phosphotyrosine modifications of CSF proteins. We carried out phosphotyrosine profiling of CSF using an anti-phosphotyrosine antibody-based enrichment and analysis using high resolution Orbitrap Fusion Lumos mass spectrometer. We identified 111 phosphotyrosine peptides mapping to 66 proteins, which included 24 proteins which have not been identified in CSF previously. We then validated a set of 5 tyrosine phosphorylated peptides in an independent set of CSF samples from cognitively normal subjects, using a PRM-based targeted approach. Conclusions: The findings from this deep phosphotyrosine profiling of CSF samples have the potential to identify novel disease-related phosphotyrosine-containing peptides in CSF.

Original languageEnglish (US)
Article number29
JournalClinical Proteomics
Volume15
Issue number1
DOIs
StatePublished - Sep 12 2018
Externally publishedYes

Fingerprint

Cerebrospinal fluid
Phosphotyrosine
Cerebrospinal Fluid
Tyrosine
Peptides
Biomarkers
Brain
Mass spectrometers
Neurodegenerative Diseases
Monitoring
Fusion reactions
Cerebrospinal Fluid Proteins
Phosphopeptides
Phosphorylation
Proteins
Peptide Mapping
Antibodies
Cell death
Fourier Analysis
Protein-Tyrosine Kinases

Keywords

  • CSF
  • Phosphotyrosine
  • Proteome

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Sathe, G., Na, C. H., Renuse, S., Madugundu, A., Albert, M., Moghekar, A., & Pandey, A. (2018). Phosphotyrosine profiling of human cerebrospinal fluid. Clinical Proteomics, 15(1), [29]. https://doi.org/10.1186/s12014-018-9205-1

Phosphotyrosine profiling of human cerebrospinal fluid. / Sathe, Gajanan; Na, Chan Hyun; Renuse, Santosh; Madugundu, Anil; Albert, Marilyn; Moghekar, Abhay; Pandey, Akhilesh.

In: Clinical Proteomics, Vol. 15, No. 1, 29, 12.09.2018.

Research output: Contribution to journalArticle

Sathe, G, Na, CH, Renuse, S, Madugundu, A, Albert, M, Moghekar, A & Pandey, A 2018, 'Phosphotyrosine profiling of human cerebrospinal fluid', Clinical Proteomics, vol. 15, no. 1, 29. https://doi.org/10.1186/s12014-018-9205-1
Sathe G, Na CH, Renuse S, Madugundu A, Albert M, Moghekar A et al. Phosphotyrosine profiling of human cerebrospinal fluid. Clinical Proteomics. 2018 Sep 12;15(1). 29. https://doi.org/10.1186/s12014-018-9205-1
Sathe, Gajanan ; Na, Chan Hyun ; Renuse, Santosh ; Madugundu, Anil ; Albert, Marilyn ; Moghekar, Abhay ; Pandey, Akhilesh. / Phosphotyrosine profiling of human cerebrospinal fluid. In: Clinical Proteomics. 2018 ; Vol. 15, No. 1.
@article{2fda774933fa40a9a97acdeadcf54216,
title = "Phosphotyrosine profiling of human cerebrospinal fluid",
abstract = "Background: Cerebrospinal fluid (CSF) is an important source of potential biomarkers that affect the brain. Biomarkers for neurodegenerative disorders are needed to assist in diagnosis, monitoring disease progression and evaluating efficacy of therapies. Recent studies have demonstrated the involvement of tyrosine kinases in neuronal cell death. Thus, neurodegeneration in the brain is related to altered tyrosine phosphorylation of proteins in the brain and identification of abnormally phosphorylated tyrosine peptides in CSF has the potential to ascertain candidate biomarkers for neurodegenerative disorders. Methods: In this study, we used an antibody-based tyrosine phosphopeptide enrichment method coupled with high resolution Orbitrap Fusion Tribrid Lumos Fourier transform mass spectrometer to catalog tyrosine phosphorylated peptides from cerebrospinal fluid. The subset of identified tyrosine phosphorylated peptides was also validated using parallel reaction monitoring (PRM)-based targeted approach. Results: To date, there are no published studies on global profiling of phosphotyrosine modifications of CSF proteins. We carried out phosphotyrosine profiling of CSF using an anti-phosphotyrosine antibody-based enrichment and analysis using high resolution Orbitrap Fusion Lumos mass spectrometer. We identified 111 phosphotyrosine peptides mapping to 66 proteins, which included 24 proteins which have not been identified in CSF previously. We then validated a set of 5 tyrosine phosphorylated peptides in an independent set of CSF samples from cognitively normal subjects, using a PRM-based targeted approach. Conclusions: The findings from this deep phosphotyrosine profiling of CSF samples have the potential to identify novel disease-related phosphotyrosine-containing peptides in CSF.",
keywords = "CSF, Phosphotyrosine, Proteome",
author = "Gajanan Sathe and Na, {Chan Hyun} and Santosh Renuse and Anil Madugundu and Marilyn Albert and Abhay Moghekar and Akhilesh Pandey",
year = "2018",
month = "9",
day = "12",
doi = "10.1186/s12014-018-9205-1",
language = "English (US)",
volume = "15",
journal = "Clinical Proteomics",
issn = "1542-6416",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Phosphotyrosine profiling of human cerebrospinal fluid

AU - Sathe, Gajanan

AU - Na, Chan Hyun

AU - Renuse, Santosh

AU - Madugundu, Anil

AU - Albert, Marilyn

AU - Moghekar, Abhay

AU - Pandey, Akhilesh

PY - 2018/9/12

Y1 - 2018/9/12

N2 - Background: Cerebrospinal fluid (CSF) is an important source of potential biomarkers that affect the brain. Biomarkers for neurodegenerative disorders are needed to assist in diagnosis, monitoring disease progression and evaluating efficacy of therapies. Recent studies have demonstrated the involvement of tyrosine kinases in neuronal cell death. Thus, neurodegeneration in the brain is related to altered tyrosine phosphorylation of proteins in the brain and identification of abnormally phosphorylated tyrosine peptides in CSF has the potential to ascertain candidate biomarkers for neurodegenerative disorders. Methods: In this study, we used an antibody-based tyrosine phosphopeptide enrichment method coupled with high resolution Orbitrap Fusion Tribrid Lumos Fourier transform mass spectrometer to catalog tyrosine phosphorylated peptides from cerebrospinal fluid. The subset of identified tyrosine phosphorylated peptides was also validated using parallel reaction monitoring (PRM)-based targeted approach. Results: To date, there are no published studies on global profiling of phosphotyrosine modifications of CSF proteins. We carried out phosphotyrosine profiling of CSF using an anti-phosphotyrosine antibody-based enrichment and analysis using high resolution Orbitrap Fusion Lumos mass spectrometer. We identified 111 phosphotyrosine peptides mapping to 66 proteins, which included 24 proteins which have not been identified in CSF previously. We then validated a set of 5 tyrosine phosphorylated peptides in an independent set of CSF samples from cognitively normal subjects, using a PRM-based targeted approach. Conclusions: The findings from this deep phosphotyrosine profiling of CSF samples have the potential to identify novel disease-related phosphotyrosine-containing peptides in CSF.

AB - Background: Cerebrospinal fluid (CSF) is an important source of potential biomarkers that affect the brain. Biomarkers for neurodegenerative disorders are needed to assist in diagnosis, monitoring disease progression and evaluating efficacy of therapies. Recent studies have demonstrated the involvement of tyrosine kinases in neuronal cell death. Thus, neurodegeneration in the brain is related to altered tyrosine phosphorylation of proteins in the brain and identification of abnormally phosphorylated tyrosine peptides in CSF has the potential to ascertain candidate biomarkers for neurodegenerative disorders. Methods: In this study, we used an antibody-based tyrosine phosphopeptide enrichment method coupled with high resolution Orbitrap Fusion Tribrid Lumos Fourier transform mass spectrometer to catalog tyrosine phosphorylated peptides from cerebrospinal fluid. The subset of identified tyrosine phosphorylated peptides was also validated using parallel reaction monitoring (PRM)-based targeted approach. Results: To date, there are no published studies on global profiling of phosphotyrosine modifications of CSF proteins. We carried out phosphotyrosine profiling of CSF using an anti-phosphotyrosine antibody-based enrichment and analysis using high resolution Orbitrap Fusion Lumos mass spectrometer. We identified 111 phosphotyrosine peptides mapping to 66 proteins, which included 24 proteins which have not been identified in CSF previously. We then validated a set of 5 tyrosine phosphorylated peptides in an independent set of CSF samples from cognitively normal subjects, using a PRM-based targeted approach. Conclusions: The findings from this deep phosphotyrosine profiling of CSF samples have the potential to identify novel disease-related phosphotyrosine-containing peptides in CSF.

KW - CSF

KW - Phosphotyrosine

KW - Proteome

UR - http://www.scopus.com/inward/record.url?scp=85053251537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053251537&partnerID=8YFLogxK

U2 - 10.1186/s12014-018-9205-1

DO - 10.1186/s12014-018-9205-1

M3 - Article

AN - SCOPUS:85053251537

VL - 15

JO - Clinical Proteomics

JF - Clinical Proteomics

SN - 1542-6416

IS - 1

M1 - 29

ER -